CCC
BSX icon

Crescent Capital Consulting’s Boston Scientific BSX Stock Holding History

Crescent Capital Consulting’s Portfolio BSX Stock Details BSX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-100
Closed -$4K – 586
2021
Q2 		$4K Hold
100
– – ﹤0.01% 413
2021
Q1 		$4K Buy
+100
New +$3.79K ﹤0.01% 423

Other funds holding BSX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BG
Bollard Group Boston, Massachusetts $3.39B AUM 1.06% 1-Year Est. Return

Crescent Capital Consulting's BSX Position: Q3 2021 in Review

Crescent Capital Consulting sold out of Boston Scientific (BSX) in Q3 2021, closing a stake of 100 shares — an estimated $4K sold.

Crescent Capital Consulting first reported a position in BSX in Q1 2021 and held it in 2 quarters. The position peaked at $4K in Q2 2021. 877 funds tracked by Wall St. Rank hold BSX as of Q3 2021.

  • Crescent Capital Consulting reported no remaining Boston Scientific position as of Q3 2021 after selling out during the quarter.
  • Crescent Capital Consulting sold 100 Boston Scientific shares in Q3 2021, an estimated $4K.
  • Crescent Capital Consulting first reported a position in Boston Scientific in Q1 2021 and held it in 2 quarters.
  • Crescent Capital Consulting's Boston Scientific position peaked at $4K in Q2 2021.
  • 877 funds tracked by Wall St. Rank held Boston Scientific as of Q3 2021.

Based on Crescent Capital Consulting's 13F filing for Q3 2021, filed 12 Oct 2021.